Patients in UK cancer trials quadruples
November 11, 2010Research and Development Cancer Research UK, NCRI, National Cancer Research Institute, UK clinical research, cancer trials
The number of cancer patients in the UK participating in clinical studies has quadrupled in the last decade, according to …
Novartis drops late stage lung cancer candidate
November 11, 2010Research and Development ASA404, Antisoma, NSCLC, Novartis, cancer research, lung cancer, non small cell lung cancer, non-small cell lung cancer
Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its …
Digital for digital’s sake is out
November 10, 2010Medical Communications digital creativity, digital marketing, ipad, seven stones, youtube
Creativity in the digital world is twofold. On the one hand there is technical wizardry and, on the other, there …
RSA expands global team
November 10, 2010Business Services Matthew Edwards, Michelle Bosshard, Yildiz Biloglu, Zaki Sellam, appointment, business services, rsa
Life sciences executive search and interim management company RSA has made a number of appointments and internal promotions across its …
Sanofi’s C diff vaccine fast tracked by FDA
November 10, 2010Research and Development C diff, C diff vaccine, C difficile, Clostridium difficile, FDA, FDA fast-track, Sanofi, Sanofi Pasteur
A new vaccine aimed at preventing C difficile infections has been fast tracked by the FDA. The regulator’s decision signals …
Genzyme again snubs suitor Sanofi
November 10, 2010Research and Development, Sales and Marketing Campath, Chris Viehbacher, Genzyme, Henri Termeer, Orphan Drugs, Plavix, Sanofi, Sanofi-Aventis, manufacturing compliance
Genzyme has once again snubbed Sanofi-Aventis as the French pharma firm continues its pursuit of the beleaguered biotech company. Henri …
Bayer rebrands pharma division
November 10, 2010Medical Communications, Sales and Marketing Bayer Healthcare, Bayer cross, Byaer Schering Pharma, Marijn Dekkers, Xarelto, prix galien
The name Bayer Schering Pharma has been consigned to the corporate dustbin as its parent group institutes a branding shake-up. …
NICE limits access to cancer drugs, study confirms
November 10, 2010Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, IPSOR, Maximilian Lebmeier, NICE, hta
NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests. The …
Pfizer and Boehringer pilot COPD campaign
November 9, 2010Medical Communications Boehringer Ingelheim, COPD, Pfizer, Salford, chronic bronchitis, chronic obstructive pulmonary disease, emphysema
Pfizer and Boehringer Ingelheim have mobilised a soap opera star, painted rugby players and a special ‘breathing bus’ for a …
Digital Pharma: Online health information reduces costs
November 9, 2010Medical Communications Digital Pharma blog, Football Fan Fitness Challenge, NHS Choices, alcohol tracker iPhone app, online health information, patient information
The number of people using the official NHS website rose 10% in the last year, making it the most popular …
Improving Clinical Site Productivity
November 9, 2010Sales and Marketing Kinapse, White paper
There are a number of factors in the industry that make clinical trials more costly, more time-consuming and requiring more …
Lilly bolsters diagnostics presence with Avid acquisition
November 9, 2010Research and Development Alzheimer's disease, Alzheimer’s disease, Avid Radiopharma, Eli Lilly, diabetes, emagacestat, florbetapir, lilly
Eli Lilly has acquired specialist diagnostics firm Avid Radiopharma in a deal that will bolster its diagnostics business. Philadelphia-based Avid …
Novartis signs Middle East vaccine production deal
November 9, 2010Manufacturing and Production Agrippal, Arabio, Novartis, Quinvaxem, meningitis vaccine Menveo, vaccines
Novartis has forged an alliance with a Saudi Arabian manufacturer to help it expand its vaccines business in the Middle …
Cambrex buys Zenara to enter nicotine replacement market
November 9, 2010API, Cambrex, Cambrex Zenara, India, Pharmaceutical ingredients, Zenara Pharma, generic APIs, nicotine replacement
Pharmaceutical ingredient manufacturer Cambrex has taken a majority stake in Indian formulator Zenara Pharma for $20 million in a move …
Pharma manufacturing news in brief
November 9, 2010Manufacturing and Production Genentech, Hovione, Jacobs Engineering, Laureate Pharma, Recipharm, contract manufacturing, pharma manufacturing
Hovione wins a patent dispute, Genentech is awarded for a manufacturing plant and there are new contracts for Recipharm, Jacobs …
Late stage trial boost for Pfizer’s arthritis drug tasocitinib
November 8, 2010JAK inhibitors, Pfizer, arthritis, tasocitinib
Pfizer’s rheumatoid arthritis treatment tasocitinib has met its two of its three primary endpoints in a phase III trial. Primary …
Trial failure for Merck Serono’s Parkinson’s candidate
November 8, 2010Research and Development Merck Serono, Newron Pharmaceuticals, Parkinson's disease, dopamine agonists, levodopa, safinamide
Merck Serono’s new alpha-aminoamide safinamide has failed to reach its primary endpoint in a study with Parkinson’s disease patients. Merck …
Recycling pharma marketing research
November 8, 2010Medical Communications, Sales and Marketing Insight Marketing Systems, market research, marketing research, pharma marketing research
Recycling is in vogue. Not just in the consumer market, but across business sectors too. But recycling in the market …
GCI bags Novartis’ social media director
November 8, 2010Medical Communications GCI Health, Mark Davis, Novartis, appointment, medical communications
Novartis Pharmaceuticals’ former social media director Mark Davis has moved to GCI Health. He has been appointed to lead the …
NICE ‘surprised’ at downgrading of its role
November 5, 2010Sales and Marketing Andrew Dillon, GP prescribing deicisions, NICE, QALY, incremental cost-effectiveness ratio, value-based pricing
NICE received no warning that its health technology assessment role is to be downgraded, the watchdog’s head has admitted. In …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
